Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Rhea-AI Summary

Impel Pharmaceuticals (NASDAQ: IMPL) announced a live webcast on November 14, 2022, at 8:30 a.m. ET to disclose its third-quarter 2022 financial results and provide a business update. The webcast can be accessed through the company’s investor website. Impel is focused on creating transformative therapies for diseases with high unmet medical needs, including Trudhesa® for treating migraines and INP105 for managing agitation in autism patients.

Positive

• Plans to report third-quarter 2022 financial results could signal transparency and investor engagement.
• Development of INP105 for autism adds potential growth avenues in underserved markets.

Negative

• None.

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update.

To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers and is developing treatments that pair its proprietary POD^® technology with well-established therapeutics. In addition to Trudhesa^® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit www.ImpelPharma.com

Contact:

Media Relations
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com

Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com

FAQ

When will Impel Pharmaceuticals announce its third-quarter 2022 financial results?

Impel Pharmaceuticals will announce its third-quarter 2022 financial results on November 14, 2022.

What technology does Impel Pharmaceuticals use in its treatments?

Impel Pharmaceuticals uses its proprietary POD® technology in its treatments.

What is Impel's current approved product?

Impel Pharmaceuticals currently has Trudhesa® nasal spray approved in the U.S. for acute migraine treatment.

What is the stock symbol for Impel Pharmaceuticals?

The stock symbol for Impel Pharmaceuticals is IMPL.